About BioGenerator
BioGenerator is a venture capital firm founded in 2003. It is primarily based out of St. Louis, United States. As of Feb 2026, BioGenerator is an active investor, having invested in 56 companies, with 2 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Food and Agriculture Tech and High Tech. Most recently it participated in the $***** Seed round of Pairidex Overall, BioGenerator portfolio has seen 1 IPO and 9 acquisitions including key companies like WellSky, Galera and CoverCress. A lot of funds co-invest with BioGenerator, with names like Missouri Technology sharing a substantial percentage of its portfolio. BioGenerator has team of 24 people.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series A & 3 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
BioGenerator's List of Top Investments
BioGenerator has a portfolio of 56 companies. Their most notable investments are in Wugen and Mobius Therapeutics.Their portfolio spans across United States, Germany and Ireland. They have invested in Life Sciences, Food and Agriculture Tech, High Tech and 8 other sectors, across stages such as Seed, Series A and 3 more. Here is the list of top investments by BioGenerator:
1. WellSky
Provider of a health care management platform for providers and patients. It provides performance management and information software systems for acute, non-acute, community-based care, healthcare providers, accountable care organizations, and others. It also offers scheduling software for enterprises, long-term care plans, and behavioral health management.
Key facts about WellSky
- Founded Year: 1980
- Location: Overland Park (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $1.66M
- Employee Count: 2,481 as on Jun 30, 2026
- Investors: Leonard Green and Partners, Georgian and 5 Others
- Latest Funding Round: Unattributed, Jul 20, 2020, $*****
- Highlight: Acquired
2. Geneoscopy
Developer of non-invasive biomarker tests for colorectal cancer. The flagship assay analyzes stool samples for a panel of disease-associated mRNA biomarkers using a proprietary diagnostic algorithm to detect colorectal cancer. The company plans that its assay will be used to screen patients in need of a more invasive colonoscopy.
Key facts about Geneoscopy
- Founded Year: 2015
- Location: St. Louis (United States)
- Stage: Series C
- Total Funding till date: $219M
- Employee Count: 71 as on Jun 30, 2026
- Investors: Innovatus Capital Partners, PavLyfe and 18 Others
- Latest Funding Round: Series C, Jan 08, 2025, $*****
- Highlight: Editors' Pick
3. Galera
Developer of chemoprotective agents for oral mucositis associated with chemotherapy. The lead candidate, GC4419, is a first-in-class, small-molecule enzyme mimetic that converts superoxide to hydrogen peroxide and molecular oxygen.
Key facts about Galera
- Founded Year: 2009
- Location: Malvern (United States)
- Stage: Public
- Total Funding till date: $144M
- Employee Count: 10 - 49 as on Mar 01, 2026
- Investors: New Enterprise Associates, Novo Holdings and 18 Others
- Latest Funding Round: Series C, Sep 19, 2018, $*****
- Highlight: Public
4. Wugen
Developer of CAR-T cell therapy for treating T-cell malignancies. The company has developed an allogeneic CAR-T therapy platform for the treatment. Deletion of the T-cell receptor (TCR) enables the use of T-cells from healthy donors without the risk of life-threatening Graft vs. Host Disease (GvHD). It has developed a pipeline for Head & Neck Cancer, Melanoma, and Solid Tumors.
Key facts about Wugen
- Founded Year: 2018
- Location: St. Louis (United States)
- Stage: Series C
- Total Funding till date: $251M
- Employee Count: 51 as on Jun 30, 2026
- Investors: Aisling Capital, Tybourne Capital Management and 11 Others
- Latest Funding Round: Series C, Aug 22, 2025, $*****
- Highlight: Editors' Pick
Developer of therapeutics for the treatment of interventional immuno-oncology. The company is engaged in the development of a proprietary novel drug product for use in an in situ autologous cancer vaccine (inCVAX) for the treatment of metastatic solid tumors. The technology uses proprietary N-dihydro-galacto-chitosan, a carbohydrate polymer, which enhances the antigen uptake, and stimulates immune response when injected in combination with checkpoint inhibitors after laser treatment.
Key facts about Immunophotonics
- Founded Year: 2008
- Location: St. Louis (United States)
- Stage: Series B
- Total Funding till date: $28.1M
- Employee Count: 20 as on Jun 30, 2026
- Investors: Gershon Capital, iSelect Fund and 12 Others
- Latest Funding Round: Conventional Debt, Feb 29, 2024, $*****
- Highlight: Editors' Pick
BioGenerator's Year-on-Year Investment Trends
BioGenerator has invested in 56 companies over the last 16 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 2 investments, while as of Feb 2026, it has made 1 investment in this year. Its most recent first time investment was in Pairidex and most recent follow-on round was in Plastomics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 1 | 1 | 2 |
2024 | 1 | 1 | 2 |
2023 | 3 | 0 | 3 |
2022 | 2 | 0 | 2 |
2021 | 8 | 5 | 13 |
2020 | 0 | 1 | 1 |
2019 | 1 | 0 | 1 |
2018 | 1 | 2 | 3 |
2017 | 2 | 0 | 2 |
BioGenerator's Investments by Stage
BioGenerator has made 19 investments in Seed stage with an average round size of $953K, 14 investments in Series A stage with an average round size of $3.32M, 2 investments in Series B stage with an average round size of $105M, 1 investment in Grant (prize money) stage with an average round size of $170K and 1 investment in Series C stage with an average round size of $123M.Stage of entry | No. of Investments |
|---|---|
Seed | 19 |
Series A | 14 |
Series B | 2 |
Grant (prize money) | 1 |
Series C | 1 |
Note: We have considered here, only first round of investments
BioGenerator's Investments by Sector
BioGenerator has a diverse portfolio, with companies operating in the Life Sciences, Food and Agriculture Tech, High Tech, Healthcare and Sustainability Tech. Notably, it has invested in 47 Enterprise (B2B) companies, 43 Tech companies, 13 Software companies and at least 6 companies focusing on Saas.Sector | No. of Investments |
|---|---|
Life Sciences | 23 |
Food and Agriculture Tech | 8 |
High Tech | 8 |
Healthcare | 5 |
Sustainability Tech | 5 |
Others | 14 |
Note: We have considered here, only first round of investments
BioGenerator's Investments by Geography
BioGenerator has made most investments in United States (36), followed by Ireland where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 36 |
Ireland | 1 |
Note: We have considered here, only first round of investments
BioGenerator's recent investments
BioGenerator has made 1 investments in 2026 so far - Pairidex.Here are the most recent investments by BioGenerator:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Feb 23, 2026 | United States | Seed | 6178 | - | |
Oct 27, 2025 | United States | Series B | 4784 | ||
Aug 22, 2025 | United States | Series C | 1205 | [+1] | |
Jul 16, 2024 | United States | Seed | 3671 | [+1] | |
Jul 09, 2024 | United States | Seed | 4580 |
IPOs and Publicly Listed companies in BioGenerator's Portfolio
1 of BioGenerator's portfolio company became public - Galera. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Nov 2019 at marketcap of $301MHere are BioGenerator's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Nov 08, 2019 | May 11, 2010 | Seed | 3784 |
Acquired companies in BioGenerator's Portfolio
9 companies from BioGenerator's portfolio have been acquired. The most recent acquisition was Peptyde Bio in Dec 2023 by Invaio Tech for $*****.Here are BioGenerator's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 07, 2023 | Nov 15, 2022 | Seed | 1554 | |
Aug 01, 2022 | May 11, 2015 | Series A | 7713 | |
Apr 19, 2022 | - | - | 4181 | |
Apr 19, 2022 | - | - | 6255 | |
Nov 15, 2021 | - | - | 1598 |
_1545120815496.png?devicePixelRatio=2&height=20&width=20){kind=logo}
_1581487527609.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Team profile of BioGenerator
BioGenerator has a team of 24 members including 8 Venture Partners and 4 Principals located in United States. BioGenerator's team does not sit on the board of any company as of now.Here is a list of top team members in BioGenerator:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Venture Partner | - | - | ||
Venture Partner | Boston | - | ||
Venture Partner | Boston | - | ||
Venture Partner | St. Louis | - | ||
Venture Partner | St. Louis | - | ||
Venture Partner | - | - | ||
Venture Partner | St. Louis | - | - | |
Venture Partner | St. Louis | - | ||
Principal | St. Louis | - | ||
Principal | St. Louis | - | ||
Principal | New York City | - |
Co-investors of BioGenerator
Over the past 16 years, 162 investors have co-invested in BioGenerator's portfolio companies. This includes funds and angels.
- Invested before BioGenerator: Missouri Technology, Cultivation Capital and 15 others have invested in rounds before BioGenerator. There are 5 companies where Missouri Technology has invested before BioGenerator and 2 companies where Cultivation Capital has invested before BioGenerator.
- Top Co-investors of BioGenerator: 34 investors entered a company along with BioGenerator. These include investors like Missouri Technology (7 companies).
- Invested after BioGenerator: A total of 111 investors have invested in BioGenerator's portfolio after their investments. Top Investors include HHS (10 companies), Missouri Technology (4 companies) and iSelect Fund (3 companies).
Recent News related to BioGenerator
•
Plastomics Announces Initial Close of Series B Financing to Advance Groundbreaking Corn Chloroplast Transformation Technologyintelligence360•Nov 17, 2025•BioGenerator, SDH Capital, Lewis & Clark Partners, Missouri Technology and 2 others
•
Plastomics Announces Initial Close of Series B Financing to Advance Corn TechnologyPR Newswire•Oct 27, 2025•Levi's, Fulcrum Global Capital, Plastomics, BioGenerator and 4 others
•
•
Solis Agrosciences Secures Series A Funding from Cultivation Capital to fuel Business GrowthBenzinga•Feb 25, 2025•Solis Mammography, Cultivation Capital, Solis, Hermann Companies and 2 others
•
Maximum Fidelity Surgical Nets $2.25M for New Simulation CenterMedical Product Outsourcing•Aug 01, 2024•MaxFi, St. Louis Arch Angels, BioGenerator, Missouri Technology
•
•
Maximum Fidelity Surgical Simulations Completes Seed Funding RoundBusiness Wire•Jul 09, 2024•Missouri Technology, BioGenerator, St. Louis Arch Angels, MaxFi
•
Former head of St. Louis startup investor joins local firm as CEOThe Business Journals•Jan 12, 2024•Solis, BioGenerator
•
•
Metabolomics Research Services Firm Panome Bio Raises $6MGenomeWeb•Mar 15, 2023•Panome Bio, Telegraph Hill Partners, BioGenerator
